Logo

CRL

Charles River Laboratories International, Inc.

CRL

Charles River Laboratories International, Inc. • NYSE
$178.14 ▼ -0.45% (-0.80)
Market Cap $8.77 B
52w High $203.01
52w Low $91.86
Dividend Yield 0%
P/E -116.43
Volume 225.77K
Outstanding Shares 49.22M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.005B ▼ $204.993M ▼ $54.422M ▲ 5.416% ▲ $1.11 ▲ $197.767M ▼
Q2-2025 $1.032B ▲ $256.933M ▲ $52.326M ▲ 5.07% ▲ $1.06 ▲ $220.892M ▲
Q1-2025 $984.168M ▼ $243.063M ▼ $25.469M ▲ 2.588% ▲ $0.5 ▲ $184.226M ▲
Q4-2024 $1.003B ▼ $451.931M ▲ $-215.699M ▼ -21.515% ▼ $-4.22 ▼ $-86.453M ▼
Q3-2024 $1.01B $231.616M $68.679M 6.801% $1.34 $209.723M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $207.67M ▲ $7.514B ▼ $4.063B ▼ $3.405B ▲
Q2-2025 $182.824M ▼ $7.561B ▼ $4.161B ▼ $3.353B ▲
Q1-2025 $229.356M ▲ $7.582B ▲ $4.341B ▲ $3.194B ▼
Q4-2024 $194.606M ▼ $7.528B ▼ $4.02B ▼ $3.462B ▼
Q3-2024 $210.171M $8.004B $4.176B $3.782B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $55.556M ▲ $213.826M ▲ $-33.696M ▲ $-152.616M ▲ $24.48M ▲ $178.246M ▲
Q2-2025 $52.693M ▲ $204.603M ▲ $-37.339M ▲ $-226.921M ▼ $-46.988M ▼ $169.305M ▲
Q1-2025 $25.878M ▲ $171.697M ▲ $-45.479M ▲ $-105.325M ▼ $26.158M ▲ $112.373M ▲
Q4-2024 $-213.747M ▼ $159.362M ▼ $-76.104M ▼ $-75.879M ▲ $-6.07M ▼ $83.746M ▼
Q3-2024 $70.295M $251.792M $-21.324M $-207.536M $30.636M $213.071M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Discovery and Safety Assessment
Discovery and Safety Assessment
 $600.00M ▲$590.00M ▼$620.00M ▲$600.00M ▼
Manufacturing Support
Manufacturing Support
 $190.00M ▲$180.00M ▼$200.00M ▲$190.00M ▼
Research Models and Services
Research Models and Services
 $200.00M ▲$210.00M ▲$210.00M ▲$210.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown meaningfully over the last several years, but it flattened and dipped slightly in the most recent year. The bigger story is profitability: margins have narrowed sharply, with operating profit and overall earnings falling very hard recently after several strong years. This suggests a mix of higher costs, integration or restructuring charges, pricing pressure, or a less favorable business mix. Historically, the company has been solidly profitable with good earnings per share, but the latest year shows that its earnings power can be volatile when conditions turn or when it invests heavily. Investors will want to understand whether this earnings compression is temporary or reflects a more structural step-down in margins.

Balance Sheet

Balance Sheet The balance sheet shows a business that has scaled up over time, with total assets and shareholder equity rising steadily. Debt has increased compared with a few years ago, but it has recently edged down, which is a mild positive. Cash on hand is relatively modest, so the company relies on ongoing cash generation and credit access rather than a large cash cushion. Overall, leverage looks manageable but not trivial, meaning the company has some financial flexibility but also needs to keep profitability and cash flow healthy to comfortably service its obligations and fund growth initiatives.

Cash Flow

Cash Flow Despite weaker reported earnings in the latest year, cash generation from operations has actually improved versus earlier years. Free cash flow has remained positive every year and has trended upward over time, even after funding a sizable and fairly consistent level of capital spending. This pattern suggests that the underlying business still throws off solid cash, and that some of the recent hit to earnings may be driven by non-cash items or timing effects. The company appears able to self-fund a meaningful portion of its investments, which supports ongoing expansion and innovation without over-reliance on new debt or equity.

Competitive Edge

Competitive Edge Charles River holds a strong niche in the drug discovery and preclinical research ecosystem. Its main advantage is breadth: it offers a wide, integrated suite of services from early discovery through safety testing, acting as a one-stop partner for pharma and biotech clients. This integration creates switching costs and builds deep, long-term relationships, especially given its regulatory track record and specialized expertise in toxicology and research models. At the same time, it operates in a competitive CRO market, facing pressure from other global players, in‑house capabilities at large pharma, and cyclical swings in biotech funding. Its position can be described as a solid but not unassailable moat, reliant on sustained service quality, scientific depth, and execution.

Innovation and R&D

Innovation and R&D The company is leaning heavily into innovation to reinforce its moat. It is investing in digital platforms and AI-driven discovery tools like the Logica platform, which aims to shorten timelines from target identification to preclinical candidates. Scientifically, it is pushing advanced models such as 3D tumoroids, patient-derived xenografts, and humanized mice that better mirror human biology. It is also moving into newer testing approaches that reduce reliance on animal models, including organoids, organs-on-chips, and in silico methods. These efforts, combined with targeted acquisitions and collaborations, are designed to keep Charles River at the center of evolving drug development methods, but they require ongoing capital, talent, and careful integration to translate into sustained financial returns.

Summary

Charles River today looks like a strategically important, cash-generative research partner that is working through a period of profit pressure. The business has grown significantly over the past several years and maintains a differentiated position as an integrated provider across the preclinical research spectrum. Its balance sheet carries meaningful but manageable debt, backed by consistent free cash flow. The main near-term concern is the sharp deterioration in earnings and margins in the most recent year, which raises questions about cost structure, pricing power, and business mix. On the opportunity side, the company is investing in AI, digital platforms, and next-generation testing methods that align with long-term industry trends and regulatory shifts. How well Charles River converts these strategic initiatives into stable, higher-quality earnings will be a key factor shaping its risk–reward profile going forward.

NEWS

November 18, 2025 · 8:00 AM UTC

SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers

Read more

November 17, 2025 · 8:00 AM UTC

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Read more

November 5, 2025 · 7:01 AM UTC

Charles River Laboratories Provides Update on Strategic Review

Read more

November 5, 2025 · 7:00 AM UTC

Charles River Laboratories Announces Third-Quarter 2025 Results

Read more

October 27, 2025 · 7:17 PM UTC

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Read more